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Towards the development of small molecule MO25-binders as 
potential indirect SPAK/OSR1 kinase inhibitors 
Hachemi Kadri,[a] Mubarak A. Alamri,[a] Iva H. Navratilova,[b] Luke J. Alderwick,[c] Nigel S. Simpkins,[d] 
and Youcef Mehellou*[a][e]  
 
Abstract: The binding of the scaffolding protein MO25 to SPAK and 
OSR1 protein kinases, which regulate ion homeostasis, causes up to 
100-fold increase in their catalytic activity. Since various animal 
models showed that the inhibition of SPAK and OSR1 lowers blood 
pressure, we herein present a novel indirect approach for inhibiting 
SPAK and OSR1 kinases by targeting their protein partner MO25. 
To explore this approach, we developed fluorescent polarization 
assay and used it in screening a small in-house library of  4,000 
compounds. This led to the identification of one molecule, HK01, as 
the first small molecule inhibitor of the MO25-dependent activation of 
SPAK and OSR1 in vitro. Our data confirms the feasibility of 
targeting this protein-protein interaction by small molecules and 
highlights the potential of these molecules to modulate ion co-
transporters and thus cellular electrolyte balance.  
STE20/SPS1-related proline-alanine-rich protein kinase 
(SPAK) and oxidative-stress-responsive kinase 1 (OSR1) are 
two serine/threonine protein kinases that share 68% sequence 
identity.[1] Although under normal conditions these kinases are 
inactive, they become activated by osmotic stress via two 
distinct mechanisms.[2] First, they get phosphorylated in a highly 
conserved threonine residue in their T-loop motifs, SPAK T233 
and OSR1 T185, by a family of protein kinases known as 
WNKs.[3] The acquired basal activity obtained following WNK-
phosphorylation is subsequently further enhanced by 80- to 100-
fold through the binding to the mouse protein-25 (MO25), a 
scaffolding protein (Fig. 1).[4] Two isoforms of MO25 exist in 
humans, MO25α and β, which are expressed in many tissues 
mostly in testis, brain, spleen, pancreas and kidney.[4] Both 
isoforms activate SPAK and OSR1 in equal measures.[4] Once 
fully activated, SPAK and OSR1 kinases phosphorylate a series 
of ion co-transporters such as the sodium-potassium-chloride 
co-transporters 1 and 2 (NKCC1 and NKCC2, respectively).[2]  
The involvement of SPAK and OSR1 kinases in regulating ion 
homeostasis via the phosphorylation of ion co-transporters and 
their possible roles in the pathogenesis of diseases that involve 
electrolyte imbalance was confirmed when it was discovered 
that genetic mutations in the SPAK and OSR1 upstream kinases 
WNKs cause hypertension in humans (Fig. 1).[5] This role was 
further emphasized by recent reports which revealed that 
mutations in the E3 ubiquitin ligases, Cul-3 and KLHL3, which 
regulate the protein levels of WNK kinases, cause hypertension 
(Fig. 1).[6] These studies suggested that the inhibition of SPAK 
and OSR1 kinases would lead to reduced blood pressure. This 
notion was confirmed by various SPAK knock-in and knock-out 
mouse models,[7] which collectively indicated that small 
molecules that inhibit the catalytic activity of SPAK and OSR1 
would have the potential to lower blood pressure and represent 
a new class of antihypertensive drugs.  
To date, few WNK-SPAK/OSR1 signalling inhibitors have 
been reported. These include those that bind directly to WNK 
kinases[8] or those that bind to SPAK/OSR1 and inhibit 
downstream WNK-signalling.[9] In this work, we explored the 
discovery of small molecules that bind to the scaffolding protein 
MO25 as means of inhibiting its binding to SPAK and OSR1 
kinases and consequently inhibiting their significant MO25-
dependent activation. 
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FIGURE 1. A GENERAL REPRESENTATION OF THE WNK-SPAK/OSR1-MO25 SIGNALLING 
CASCADE AND ITS ROLE IN THE REGULATION OF SODIUM, POTASSIUM AND CHLORIDE 
ION CO-TRANSPORTERS. 
          
 
 
 
Our pursuit of specific MO25-small molecule binders was 
inspired by the fact that MO25 binding to SPAK and OSR1 
kinases is mediated by two highly conserved tryptophan 
residues on SPAK (W382 and W384) and OSR1 (W336 and 
W338).[4] Indeed, we recently solved the crystal structure of  
MO25 in complex with the WEW motif of SPAK (unpublished 
data) and this showed that these two tryptophan residues sit in a 
hydrophobic site on MO25 (Fig. 2A) akin to how the 
pseudokinase STRADα WEF motif[10] binds to MO25. With this in 
mind, we developed a fluorescence polarization (FP) assay for 
measuring the binding of MO25 to a 16-mer WEWpS peptide 
derived from SPAK and OSR1, which contains the highly 
conserved tryptophan residues. Briefly, the 16-mer peptide 
(TEDGDWEWpSDDEMDEK) derived from human SPAK (aa. 
377-392) was synthesised with an N-terminal domain 
CCPGCCGG motif and was labelled with Lumio Green. This 
fluorophore-peptide conjugate was subsequently incubated with 
increasing concentrations of MO25 and fluorescence 
polarization was measured to determine the binding affinity, kD  
5 ± 0.9 μM (Fig. 2B). We also used a mutated version of the 
peptide where the tryptophan residues were mutated into 
alanine (TEDGDAEApSDDEMDEK) and this did not bind to 
MO25 confirming the importance of these two tryptophan 
residues of SPAK and OSR1 in mediating binding to MO25 (Fig. 
2B). Given that this assay is compatible with high throughput 
screening (HTS) technologies, we next employed it in screening 
4,000 compounds from our in-house diversity-set library of small 
molecules to identify hit small molecule MO25-binders. 
Prior to running the screen, we first studied the effect of 
DMSO on the FP signal since the library compounds were 
already dissolved in DMSO. For this, the FP assay was run in 
increasing concentrations of DMSO ranging from 0.3% to 10%. 
A final concentration of 4 % DMSO was chosen as 90% of the 
FP signal was retained (Fig. 2C). Subsequently, we investigated 
the stability of the FP signal over time. Thus, the assay was read 
at various times ranging from 20 minutes to 24 h and, 
impressively, the FP signal was stable over 24 h (Fig. 2D). 
Next, we screened 4,000 compounds form the University of 
Birmingham in-house diversity-set library of small molecules. 
The compounds were screened at a single final concentration of 
20 μM in duplicate. Six compounds were identified from the 
primary screen as possible MO25-binders since they achieved > 
30% inhibition of MO25 binding to the 16-mer WEWpS peptide. 
Further analysis of these compounds indicated that only one 
compound, HK01 (Fig. 2E, see Supplementary Information), 
was a true MO25-binder. A prior knowledge search using the 
structure of HK01 and its reported IDs did not lead to any 
results. Using the in vitro FP competition assay, HK01 was able 
to inhibit the 16-mer WEWpS peptide binding to MO25, IC50 = 78 
± 4 μM (Fig. 2F). Interestingly, a series of compounds with 
structural similarity to HK01, especially those with the 
anthracene moiety, did not show any ability to inhibit the 16-mer 
WEWpS peptide binding to MO25 at 100 μM (see 
Supplementary Information). SPR studies showed that the KD 
of HK01 towards wild-type MO25 was 127 ± 6 μM (see 
Supplementary Information).  
To explore if this inhibition of binding could be translated into 
inhibition of the catalytic activity of SPAK and OSR1 kinases, we 
run an in vitro kinase assay employing full length OSR1 T185E. 
We used this OSR1 where the T-loop threonine was mutated 
into glutamic acid, to mimic phosphorylation, as it is 
constitutively active.[3] In this assay, full length OSR1 T185E in 
the presence of MO25 showed that HK01 exerted dose-
dependent inhibition of the MO25-dependent activation of OSR1 
T185E (Fig. 2G). Although MO25 binding to SPAK and OSR1 
kinases is thought to be 1:1, previous studies[4] have established 
that pronounced activation of OSR1 T185E in vitro required five 
Figure 2. HTS assay optimization and identification of HK01 as an MO25-binder. A. Co-crystal structure of MO25 (beige) in complex with the WEW peptide 
motif (green sticks) derived from human SPAK. B. Fluorescence polarization assay for measuring the binding affinity of MO25 to Lumio Green labelled 16-mer 
peptides (TEDGDWEWpSDDEMDEK, termed WEWpS or TEDGDAEApSDDEMDEK, termed AEApS). C. Effect of DMSO on the FP signal. D. Stability of the FP 
signal overtime. FP signal was recorded at 20 and 45 minutes, 1, 3 and 24 h. E. Chemical structure of HK01. F. In vitro inhibition of MO25 binding to the SPAK 
16-mer WEWpS peptide by HK01. G. In vitro ADP-Glo kinase assay of active OSR1 T185E in the absence or presence of MO25 (five molar excess). Data for 
B, C, D, F and G shown are the average signal from triplicates with SD.   
          
 
 
 
molar excess of MO25 and this led us to use high 
concentrations of the MO25 small molecule binder HK01 (Fig. 
2G). Interestingly, HK01 was unable to inhibit MST3, a protein 
kinase that belongs to the same family of kinases as SPAK and 
OSR1, in vitro even at concentrations up to 500 μM (see 
Supplementary Information). 
To further probe the ability of the hit compound HK01 to bind 
MO25 and inhibit its binding to SPAK and OSR1 protein kinases, 
we performed MO25 pull down assay in the presence and 
absence of HK01. For this, lysates from HEK293 cells, which 
endogenously express MO25, were incubated with N-terminally 
biotinylated 16-mer WEWpS peptide in the presence of 
increasing concentrations of HK01. Following 2 h incubation, 
streptavidine-biotin-16-mer WEWpS pulldown was performed 
and the pulled down material underwent blotting for MO25. As 
shown in Fig. 3, in the absence of HK01, endogenous MO25 
was pulled down by the 16-mer WEWpS peptide as expected. 
This binding, however, was abolished by the addition of 100 µM 
unlabeled 16-mer WEWpS peptide as expected. Interestingly, 
titration of increasing concentrations of HK01 resulted in the 
inhibition of MO25 binding to the 16-mer WEWpS peptide in a 
concentration dependent manner. Notably, western blotting of 
the flow through material following the streptavidine-biotin 
pulldown showed higher amounts of MO25 in samples where 
the MO25 binding to the 16-mer peptide was inhibited by the 
unlabeled 16-mer WEWpS peptide or HK01 (Fig. 3). This 
confirms that HK01 directly binds to MO25 and inhibits its 
binding to the 16-mer WEWpS peptide in HEK293 cell lysates.  
Figure 3. Competition of MO25 binding to the SPAK 16-mer WEWpS 
peptide by HK01. HEK293 cell lysates were treated with either the SPAK 16-
mer WEWpS peptide or HK01 at increasing concentrations. This was followed 
by incubation with the biotinylated version of the SPAK 16-mer WEWpS 
peptide. The pulled down material underwent blotting for MO25. The flow 
through from this pulldown experiment was probed for β-catenin as a negative 
control and MO25.  
Given the ability of HK01 to indirectly inhibit OSR1 T185E 
activity in vitro through the inhibition of its binding to MO25, we 
next investigated the ability of HK01 to inhibit the 
phosphorylation of SPAK and OSR1 physiological substrates in 
cells. In particular, we focused on the inhibition of the sodium, 
potassium and chloride co-transporter NKCC1, a known in vivo 
substrate of SPAK and OSR1 kinases.[3] For this experiment, we 
used HEK293 cells as they endogenously express WNK 
kinases, SPAK, OSR1, MO25 and NKCC1.[4] The cells were 
treated with increasing concentrations of HK01 or 10 μM of 
STOCK1S-50699[9a] for 30 minutes followed by hypotonic buffer 
to activate WNK-SPAK/OSR1 signaling.[11] Subsequently, they 
were harvested and probed for total SPAK, SPAK pS373, total 
NKCC1 and NKCC1 pT203, pT207 and pT212. The results 
show that hypotonic buffer led to a pronounced increase in the 
phosphorylation of SPAK pS373 and NKCC1 at the T203, T207 
and T212 residues indicating the activation of the WNK-
SPAK/OSR1 signaling cascade (Fig. 4).  
These phosphorylation sites were suppressed in samples 
treated with the WNK-signaling inhibitor[9b] STOCK1S-50699 as 
expected. The 16-mer WEWpS peptide, however, showed no 
inhibition of NKCC1 or SPAK S373 phosphorylation most likely 
due to lack of cellular uptake because of its molecular weight of 
approximately 1800 g/mol. Interestingly, the phosphorylation of 
NKCC1 at T203, T207 and T212 sites was inhibited by HK01 in 
concentration-dependent manner with the SPAK/OSR1-
mediated phosphorylation of NKCC1 being completely inhibited 
at high concentrations. Critically, unlike STOCK1S-50699, HK01 
had no significant effects on SPAK S373 phosphorylation 
confirming that it does not inhibit WNK kinases or their binding to 
SPAK. This reflects the ability of HK01 to inhibit MO25-
dependent activation of SPAK and OSR1 kinases. Notably, the 
HK01 was not toxic as the cells were healthy even at the high 
concentrations (2 mM) of HK01  and its effects seem to be 
specific to MO25 binding since there was no effect on the total 
levels of beta-catenin, a protein unrelated to the WNK-
SPAK/OSR1-signalling pathway (Fig. 4). 
Figure 4. Inhibition of SPAK/OSR1 kinases in HEK293 cells by HK01. 
HEK293 cells were treated with the WNK-signaling inhibitor STOCK1S50699 
(10 µM), SPAK 16-mer WEWpS peptide (100 μM) or HK01 at different 
concentrations (0.1-2 mM) for 30 minutes. Subsequently, they were either left 
untreated or treated with hypotonic buffer for 30 minutes to activate WNK-
SPAK/OSR1 signaling. The cells were then harvested and the lysates were 
probed for phospho-NKCC1 T203, T207 and T212, total NKCC1, β-catenin, 
phospho-SPAK S373, total SPAK and MO25. 
In conclusion, the work presented herein confirms the 
possibility of targeting the scaffolding protein MO25 with small 
molecules, which consequently leads to the inhibition of SPAK 
and OSR1. Indeed, we have shown that compound HK01 can 
successfully inhibit MO25 binding to SPAK and OSR1 leading to 
their in vitro inhibition without directly binding to them. Efforts 
aimed at the structural optimization of HK01 to achieve better 
          
 
 
 
binding affinity are currently ongoing and will be reported in the 
future. Collectively, our work represents a novel strategy in the 
discovery of indirect SPAK and OSR1 inhibitors, which have the 
potential to be developed into new antihypertensive drugs.  
Experimental Section 
Reagents 
Tissue-culture reagents and protein expression materials were 
purchased from Sigma Aldrich. Peptides were ordered from GLS Peptide 
Synthesis (China). STOCK1S-50699 was purchased from Vitas-M 
Laboratory, Ltd. ADP-Glo™ Kinase Assay kit was purchased from 
Promega. LumioTM Green (FlAsH-EDT2) was purchased from 
Carbosynth. HK01 was purchased from ChemBridge (ID:7182449). 
Buffers 
Cells Lysis Buffer: 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 1 mM EGTA, 
50 mM sodium fluoride, 5 mM sodium pyrophosphate, 1 mM sodium 
orthovanadate, 1% (w/v) Nonidet P40, 0.27 M sucrose, 0.1% (v/v) 2-
mercaptoethanol, 0.1 mM PMSF, 1 mM benzamidine. Bacterial lysis 
buffer: 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EGTA, 1 mM 
EDTA, 0.27 M sucrose, 0.1 mM PMSF, 1 mM benzamidine, 0.5 mg/ml 
lysosome, 0.3 mg/ml DNase and 2mM DTT. Buffer A: 50 mM Tris-HCl 
(pH 7.5), 0.1 mM EGTA and 0.1% (v/v) 2-mercaptoethanol. Normal 
buffer: bacterial lysis buffer without lysozome and DNase. High salt 
buffer: normal buffer with 500 mM NaCl. TBS-T buffer: 50 mM Tris-HCl 
(pH 7.5), 150 mM NaCl and 0.2% (v/v) Tween-20. Running buffer: 34.6 
mM SDS, 25 mM Tris-base and 1.92 M glycine. Transfer buffer: 48 mM 
Tris-base, 39 mM glycine containing 20% (v/v) methanol. Hypotonic low-
chloride buffer: 67.5 mM sodium gluconate, 2.5 mM potassium gluconate, 
0.25 mM CaCl2, 0.25 mM MgCl2, 0.5 mM Na2HPO4, 0.5 mM Na2SO4 and 
7.5 mM HEPES. SDS sample buffer (4X): 40 % glycerol, 240 mM Tris-
HCl (pH 6.8), 8% SDS, 0.04% (w/v) bromophenol blue and 5% 2-
mercaptoethanol. Blocking buffer: 10% (w/v) dried skimmed milk in TBST. 
Dialysis buffer: 50 mM Tris-HCl (pH 7.5), 150 mM NaCl and 2 mM DTT. 
Antibodies 
SPAK phospho-Ser373 [S670B], MO25α [S898A], NKCC1 [DU 6146], 
NKCC1 phospho-Thr 203+Thr 207+Thr 212 [S763B] and SPAK [S551D] 
antibodies were purchased from DSTT, University of Dundee. SPAK 
[2281S] and β-Catenin [9562S] were purchased from Cell Signalling 
Technology, GAPDH antibody [MA5-15738], anti-sheep [31480] and anti-
rabbit [31460] secondary antibodies conjugated to HRP were purchased 
from Thermo Scientific. 
Plasmids, protein expression and purification 
pGEX-6-MO25alpha [DU2945] DNA plasmid was purchased from the 
DSTT, University of Dundee and the protein was expressed and purified 
in-house as described elsewhere[10]. The OSR1 T185E protein [DU6231] 
was purchased from the DSTT, University of Dundee. 
Development of fluorescence polarization assay: 
BMG PheraStar plate reader was used to measure the fluorescence 
polarization, with an excitation and emission wavelengths of 485 nm and 
538 nm, respectively. Assays were performed using black, flat bottom 
Greiner 384-well plates in triplicate with at least twelve data points per 
curve and data analysis was completed using GraphPad Prism 7.0. 
Peptide labelling and determination of optimum fluorescent probe 
concentration 
The 16-mer TEDGDWEWpSDDEMDEK peptide derived from human 
SPAK (aa. 377-392) was synthesised with an N-terminal CCPGCCGG 
domain. The lyophilized peptide was initially suspended in 50 mM 
NH4HCO3 (pH 8). The labelling step was achieved by incubating 10 μM 
of peptide with 30 μM of FlAsH-EDT2 in 500 μL dialysis buffer in the dark 
at 4°C for 2 h. The peptides were then dialyzed for 4 h into dialysis buffer 
using a Mini Dialysis kit with 1 kD cut-off (GE Healthcare) and then for 
another 12 h with a fresh dialysis buffer. The optimum FlAsH-EDT2 
labelled peptide concentration for FP assay was determined to be 10nM 
as this concentration exhibited about ten times more fluorescence 
intensity signal compared to background controls. 
Fluorescence polarization binding and stability studies 
10 nM of FlAsH-EDT2-labelled peptide (TEDGDWEWpSDDEMDEK or 
TEDGDAEApSDDEMDEK) was mixed with MO25 at various 
concentrations (0.005-50 μM) in dialysis buffer in a final volume of 30 μL. 
The plates were incubated at RT and readings were taken at various time 
points.[12]   
DMSO tolerance 
Increasing concentrations of DMSO (0%–10% of assay volume) were 
added to the reaction mixture containing 10 nM of the FlAsH-EDT2 
labelled 16-mer peptide (TEDGDWEWpSDDEMDEK) and 5μM MO25 
protein. The reaction mixture was incubated at RT for 2 h and then 
fluorescence polarization measurements were taken. 
Fluorescence polarization competition studies 
Competitive binding experiments were performed in a total of 25 μL 
dialysis buffer. Fluorescent peptide and MO25 were used at final 
concentrations of 10nM and 5 µM respectively and DMSO was added to 
all wells and kept at final concentration of 4%. 0.05% of Tween-20 was 
used in the FP assay to prevent aggregation. For each assay, blank 
controls contained the fluorescent peptide only; negative controls 
contained the fluorescent peptide and MO25 while the 16-mer WEWpS 
was added to the fluorescent peptide and MO25 for positive controls. The 
effect of the competitors on the disruption of the interaction is expressed 
as % of control. This latter (% of control) for each dose of competitor was 
calculated using the following equation: 
% of control = (recorded FPsignal competitor - recorded FPsignal blank)/(recorded 
FPsignal control -recorded FPsignal blank) 
Where recorded FP signal blank is the average measured FP signal from 
fluorescent peptide only wells, the recorded FP signal control is the 
average FP signal from wells containing MO25 and fluorescent peptide in 
the absence of inhibitors, the recorded FP signal competitor is the FP 
signal from wells containing MO25 and fluorescent peptide in the 
presence of competitors. Dose-dependent experiments to determine the 
IC50 for HK01 were performed in the same manner using at least 12 
concentrations in 2-fold serial dilutions from 1000 μM. After 2 h 
incubation at room temperature, the fluorescence polarization 
measurements were taken as described above. 
Assay performance 
Z' factor was used to evaluate the assay quality and was calculated to be 
0.7 indicating the robustness of the assay.[13] This reported Z' factor is the 
average of 3 experiments of 16 replicates performed on different days. It 
was determined based on the following equation:    
                Z'= 1 – (3σpositive + 3σnegative) / |µpositive- µnegative|  
Where σ and µ are the standard deviations and means of the negative 
(FlAsH-EDT2-labelled peptide bound to MO25 in 4% DMSO) and positive 
(FlAsH-EDT2-labelled peptide bound to MO25 in the presence of SPAK 
16-mer WEWpS peptide) controls respectively. 
Pull-down assay  
Streptavidin beads were washed with Buffer A three times. 1.2 mg of 
HEK293 cells were pre-cleared using the prewashed streptavidin beads 
then divided into equal amounts using Eppendorf tubes. The tubes were 
then incubated with 100 µM 16-mer WEWpS peptide as a positive control 
or increasing concentrations of HK01 (0.05 mM, 0.1 mM, 0.25 mM, 0.75 
mM, 1 mM and 2 mM) for 2 h.  3 µg of the biotinylated 16-mer WEWpS 
was added to each sample for 10 mins at 4 ºC. 20 µL of the washed 
streptavidin beads slurry was added to each sample and mixed with 
roller-shaker at 4 ºC.  Following a spin-down at 3000 rpm, for 10 mins, 
the supernatant was collected and concentrations were determined using 
Bradford assay. The beads were washed 3 times more with buffer A. 
Using 4x SDS, samples were prepared for immunoblotting. 
Cell based assays 
HEK-293 cells were cultured using 6-well plates in DMEM supplemented 
with 10% (v/v) FBS, 2 mM L-glutamine, 100 units/mL penicillin and 0.1 
mg/mL streptomycin at 37 °C in a humidified 5% CO2 incubator. Cells 
were incubated with STOCK1S50699 (10 µM), SPAK 16-mer WEWpS 
peptide (100 μM) or HK01 at increasing concentrations (0.1 mM, 0.25 
mM, 0.5 mM, 0.75 mM, 1 mM and 2 mM) for 30 minutes then stimulated 
with low chloride hypotonic buffer to activate WNK signalling for 30 
minutes. Cells were then lysed with 200 µL cells lysis buffer and 
          
 
 
 
centrifuged at 12000 g at 4 ºC for 10 minutes and the supernatant was 
collected.  
Immunoblotting 
20 μg of cell lysates in SDS sample buffer were subjected to 
electrophoresis on a polyacrylamide gel and transferred to nitrocellulose 
membranes. The membranes were blocked for 1 h with 10% (w/v) 
skimmed milk powder in TBS-T. The membranes were then incubated 
with the relevant primary antibodies overnight. The blots were then 
washed six times with TBS-T to remove the primary antibody and 
subsequently incubated with secondary HRP‐conjugated antibodies. 
After repeating the washing steps, the signal was detected with the 
enhanced chemiluminescence reagent. Immunoblots were developed 
using a film automatic processor (SRX‐101; Konica Minolta Medical), and 
films were scanned with a 300‐dp1 resolution on a scanner (PowerLook 
1000; UMAX). 
ADP-Glo in vitro kinase assay 
The kinase activity was assayed using ADP-Glo kinase assay in 96-
well plate in triplicate as reported.[4] HK01 was tested at 100 µM and 500 
µM final concentrations against GST-OSR1 T185E (0.4 µM final 
concentration) in the presence and absence of 5x MO25 (2 µM final 
concentration). Kinase reactions were performed for 40 minutes at 30 °C 
with gentle agitation in 25 μL reaction buffer consisting of 50 mM Tris-HCl, 
10m MgCl2, 0.1% (v/v) 2-mercaptoethanol, 0.1 mM ATP and employing 
0.25 mM CATCHtide (RRHYYYDTHTNTYYLRTFGHNTRR). The plate 
was then developed according to the manufacturer's protocol[14]. The 
plate was subsequently read on a BMG FLUOstar Omega plate reader. 
The final DMSO concentration was 4%.     
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COMMUNICATION 
HTS screening of a small library of 
4,000 compounds led to the 
identification of one molecule, HK01, 
as a promising binder to the 
scaffolding protein MO25. This 
molecule was able to inhibit MO25-
dependent activation of SPAK and 
OSR1 protein kinases in vitro and in 
cells. Collectively, this confirms that 
MO25 is amenable to targeting by 
small molecules and this approach 
could yield useful SPAK and OSR1 
indirect kinase inhibitors. 
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